Calidi Biotherapeutics (Calidi Biotherapeutics) Cash-to-Debt : 0.10 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Calidi Biotherapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.10.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Calidi Biotherapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Calidi Biotherapeutics's Cash-to-Debt or its related term are showing as below:

CLDI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04 Med: 0.12 Max: 1.04
Current: 0.1

During the past 4 years, Calidi Biotherapeutics's highest Cash to Debt Ratio was 1.04. The lowest was 0.04. And the median was 0.12.

CLDI's Cash-to-Debt is ranked worse than
94.83% of 1527 companies
in the Biotechnology industry
Industry Median: 6.23 vs CLDI: 0.10

Calidi Biotherapeutics Cash-to-Debt Historical Data

The historical data trend for Calidi Biotherapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Calidi Biotherapeutics Cash-to-Debt Chart

Calidi Biotherapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.04

0.41

0.06

0.27

Calidi Biotherapeutics Quarterly Data
	Dec20	Sep21	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial					N/A	0.14	1.04	0.27	0.10

Competitive Comparison of Calidi Biotherapeutics's Cash-to-Debt

For the Biotechnology subindustry, Calidi Biotherapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Calidi Biotherapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Calidi Biotherapeutics's Cash-to-Debt falls into.

Calidi Biotherapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Calidi Biotherapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.949	/	(1.923	+	5.313)
	=	0.27

Calidi Biotherapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.143	/	(5.385	+	6.328)
	=	0.10

Calidi Biotherapeutics (AMEX:CLDI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Calidi Biotherapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Calidi Biotherapeutics (Calidi Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

11011 North Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037

Website

https://www.calidibio.com

Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics (Calidi Biotherapeutics) Headlines

From GuruFocus

Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV

By ACCESSWIRE • 05-17-2024